Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: Functional and biochemical aspects

Clinical and Experimental Pharmacology and Physiology

Volumn 36, Issue 4, 2009, Pages 358-366

  Toque, Haroldo A ^a   Priviero, Fernanda B M ^a   Zemse, Saiprasad M ^b   Antunes, Edson ^a   Teixeira, Cleber E ^a,b   Webb, R Clinton ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Anococcygeus muscle; cGMP; Nitric oxide; Phosphodiestarase 5

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; CARBACHOL; CYCLIC GMP; GLYCERYL TRINITRATE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

ANIMAL TISSUE; ANOCOCCYGEUS MUSCLE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG EFFECT; DRUG POTENCY; ELECTROSTIMULATION; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; MUSCLE ISOMETRIC CONTRACTION; NITRERGIC NERVE; NONHUMAN; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE RELAXATION; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ANIMALS; CARBOLINES; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GUANYLATE CYCLASE; IMIDAZOLES; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; NG-NITROARGININE METHYL ESTER; NITROGLYCERIN; OXADIAZOLES; PENILE ERECTION; PHOSPHODIESTERASE 5 INHIBITORS; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONES; TRIAZINES; VASODILATOR AGENTS;

EID: 68849128228     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.05071.x     Document Type: Article

References (48)

1. Andersson KE, Persson K. Nitric oxide synthase and nitric oxide-mediated effects in lower urinary tract smooth muscles. World J. Urol. 1994 12 : 274 80.
2. Gibson A. Phosphodiesterase 5 inhibitors and nitrergic transmission: From zaprinast to sildenafil. Eur. J. Pharmacol. 2001 411 : 1 10.
3. Toda N, Okamura T. The pharmacology of nitric oxide in the peripheral nervous system of blood vessels. Pharmacol. Rev. 2003 55 : 271 324.
4. Andersson KE, Wagner G. Physiology of penile erection. Physiol. Rev. 1995 75 : 191 236.
5. Andersson KE. Pharmacology of penile erection. Pharmacol. Rev. 2001 53 : 417 50.
6. Leone AM, Palmer RM, Knowles RG, Francis PL, Ashton DS, Moncada S. Constitutive and inducible nitric oxide synthases incorporate molecular oxygen into both nitric oxide and citrulline. J. Biol. Chem. 1991 266 : 23 790 5.
7. Maurice DH, Palmer D, Tilley DG et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol. Pharmacol. 2003 64 : 533 46.
8. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ. Res. 2003 93 : 280 91.
9. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: Relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 2001 65 : 1 52.
10. Juilfs DM, Soderling S, Burns F, Beavo JA. Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs). Rev. Physiol. Biochem. Pharmacol. 1999 135 : 67 104.
11. Boolell M, Allen MJ, Ballard SA et al. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. Res. 1996 8 : 47 52.
12. Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am. J. Cardiol. 2003 92 : M9 18.
13. Montorsi F, Briganti A, Salonia A, Montorsi P, Rigatti P. The use of phosphodiesterase type 5 inhibitors for erectile dysfunction. Curr. Opin. Urol. 2004 14 : 357 9.
14. Jackson G, Gillies H, Osterloh I. Past, present, and future: A 7-year update of Viagra (sildenafil citrate). Int. J. Clin. Pract. 2005 59 : 680 91.
15. Carson CC, Hatzichristou DG, Carrier S et al. Erectile response with vardenafil in sildenafil nonresponders: A multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. BJU Int. 2004 94 : 1301 9.
16. Giuliano F, Donatucci C, Montorsi F et al. Vardenafil is effective and well-tolerated for treating erectile dysfunction in a broad population of men, irrespective of age. BJU Int. 2005 95 : 110 16. (Pubitemid 350027199)
17. Kulkarni SK, Sharma A. Rat anococcygeus: A dynamic smooth muscle preparation for experimental pharmacology. Methods Find. Exp. Clin. Pharmacol. 1994 16 : 379 85. (Pubitemid 24316992)
18. Gibson A, McFadzean L. Biology of the anococcygeus muscle. Int. Rev. Cytol. 2001 205 : 1 35.
19. Dail WG, Carrillo Y, Walton G. Innervation of the anococcygeus muscle of the rat. Cell Tissue Res. 1990 259 : 139 46.
20. G-monomethyl l-arginine on the response of the rat anococcygeus muscle to NANC nerve stimulation. Br. J. Pharmacol. 1989 98 : 1080 2.
21. Li CG, Rand MJ. Evidence for a role of nitric oxide in the neurotransmitter system mediating relaxation of the rat anococcygeus muscle. Clin. Exp. Pharmacol. Physiol. 1989 16 : 933 8.
22. Song ZM, Brookes SJ, Costa M. NADPH-diaphorase reactivity in nerves supplying the rat anococcygeus muscle. Neurosci. Lett. 1993 158 : 221 4.
23. Mitchell JA, Sheng H, Forstermann U, Murad F. Characterization of nitric oxide synthases in non-adrenergic non-cholinergic nerve containing tissue from the rat anococcygeus muscle. Br. J. Pharmacol. 1991 104 : 289 91.
24. Cellek S, Kasakov L, Moncada S. Inhibition of nitrergic relaxations by a selective inhibitor of the soluble guanylate cyclase. Br. J. Pharmacol. 1996 118 : 137 40.
25. Fonseca M, Uddin N, Gibson A. No evidence for a significant non-nitrergic, hyperpolarising factor contribution to field stimulation-induced relaxation of the mouse anococcygeus. Br. J. Pharmacol. 1998 124 : 524 8.
26. Teixeira CE, Priviero FB, Claudino MA et al. Stimulation of soluble guanylyl cyclase by BAY 41-2272 relaxes anococcygeus muscle: Interaction with nitric oxide. Eur. J. Pharmacol. 2006a 530 : 157 65.
27. Frith D, Gibson A. Sildenafil citrate on nitrergic transmission in anococcygeus muscles from the urogenital system of male and female mice. Eur. J. Pharmacol. 2000 400 : 305 12.
28. Gillespie JS. The rat anococcygeus muscle and its response to nerve stimulation and to some drugs. Br. J. Pharmacol. 1972 45 : 404 16.
29. 2+ sensitization and the regulation of contractility in rat anococcygeus and retractor penis muscle. Biochem. Pharmacol. 2005 69 : 1483 92.
30. Briganti A, Salonia A, Gallina A et al. Drug insight: Oral phosphodiesterase type 5 inhibitors for erectile dysfunction. Nat. Clin. Pract. Urol. 2005 2 : 239 47. (Pubitemid 40823126)
31. Werkstrom V, Svensson A, Andersson KE, Hedlund P. Phosphodiesterase 5 in the female pig and human urethra: Morphological and functional aspects. BJU Int. 2006 98 : 414 23.
32. Teixeira CE, Priviero FB, Webb RC. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. J. Pharmacol. Exp. Ther. 2006 316 : 654 61.
33. Toque HA, Teixeira CE, Priviero FB, Morganti RP, Antunes E, De Nucci G. Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. Br. J. Pharmacol. 2008 154 : 787 96.
34. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J. Urol. 1998 159 : 2164 71.
35. Salom JB, Burguete MC, Perez-Asensio FJ, Castello-Ruiz M, Torregrosa G, Alborch E. Relaxant effect of sildenafil in the rabbit basilar artery. Vasc. Pharmacol. 2006 44 : 10 16.
36. Giuliano F, Bernabe J, Alexandre L, Niewoehner U, Haning H, Bischoff E. Pro-erectile effect of vardenafil: In vitro experiments in rabbits and in vivo comparison with sildenafil in rats. Eur. Urol. 2003 44 : 731 6.
37. Lau LC, Adaikan PG. Mechanisms of direct relaxant effect of sildenafil, tadalafil and vardenafil on corpus cavernosum. Eur. J. Pharmacol. 2006 541 : 184 90.
38. Sakuma I, Akaishi Y, Tomioka H, Sato A, Kitabatake A, Hattori Y. Interactions of sildenafil with various coronary vasodilators in isolated porcine coronary artery. Eur. J. Pharmacol. 2002 437 : 155 63.
39. Simonsen U, Contreras J, Garcia-Sacristán A, Martinez AC. Effect of sildenafil on non-adrenergic non-cholinergic neurotransmission in bovine penile small arteries. Eur. J. Pharmacol. 2001 412 : 155 69.
40. Thompson CS, Mumtaz FH, Khan MA et al. The effect of sildenafil on corpus cavernosal smooth muscle relaxation and cyclic GMP formation in the diabetic rabbit. Eur. J. Pharmacol. 2001 425 : 57 64.
41. Yoo KY, Kim HS, Moon JD, Lee J. Sildenafil (Viagra) augments sodium nitroprusside-induced but not nitroglycerin-induced hypotension in dogs. Anesth. Analg. 2002 94 : 1505 9.
42. Vemulapalli S, Kurowski S. Sildenafil relaxes rabbit clitoral corpus cavernosum. Life Sci. 2000 67 : 23 9.
43. Saenz de Tejada I, Angulo J, Cuevas P et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int. J. Impot. Res. 2001 13 : 282 90.
44. 3H]Sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP. Mol. Pharmacol. 2003 63 : 1364 72.
45. Sung BJ, Hwang KY, Jeon YH et al. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature 2003 425 : 98 102.
46. Blount MA, Beasley A, Zoraghi R et al. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol. Pharmacol. 2004 66 : 144 52.
47. Carrier S. Pharmacology of phosphodiesterase 5 inhibitors. Can. J. Urol. Suppl. 2003 1 : 12 16.
48. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int. 2005 96 : 257 80.